Replies to post #16397 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Despite the multitude of Humira biosimilars in the pipeline and the general lack of clarity on those applications, but after re-reading the [FDA] draft guidance the early articles and comments -- I am going out on a limb and predicting that MNTA will be granted the first AB rated interchangeable Humira

It could well happen; the upside is colossal if it does.

p.s. ABBV just raised the US price of Humira 8.4% (

In today's drug price increase news, per Raymond James, $ABBV raised Humira price 8.4% pic.twitter.com/bHjWSfeBhq

— Meg Tirrell (@megtirrell) January 18, 2017

). Every little bit helps.

[DewDiligence]

Modest support for your prediction that MNTA will eventually have the sole interchangeable Humira FoB:

#msg-128336237

Feedback welcome.